Drug Profile
Omega-3-acid ethyl esters therapeutics - Trygg Pharma
Alternative Names: AKR-963; AKR-996; OmtrygLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Trygg Pharma
- Class Antihyperlipidaemics; Omega 3 fatty acids
- Mechanism of Action Lipid modulators; Triglyceride modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertriglyceridaemia
- No development reported Myocardial infarction
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for research development in Myocardial-infarction(Adjunctive treatment, Prevention) in Norway (PO, Capsule)
- 27 Mar 2015 Early research in Myocardial infarction (Prevention, Adjunctive treatment) in Norway (PO) (Trygg Pharma, pipeline, March 2015)
- 24 Jun 2014 Launched for Hypertriglyceridaemia (Adjunctive treatment) in USA (PO)